Compare CAAP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAP | FOLD |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2018 | 2007 |
| Metric | CAAP | FOLD |
|---|---|---|
| Price | $26.01 | $14.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $25.85 | ★ $27.56 |
| AVG Volume (30 Days) | 138.6K | ★ 20.9M |
| Earning Date | 11-24-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,872,934,000.00 | $598,704,000.00 |
| Revenue This Year | $5.19 | $21.49 |
| Revenue Next Year | $7.63 | $18.46 |
| P/E Ratio | $23.84 | ★ N/A |
| Revenue Growth | ★ 25.19 | 21.28 |
| 52 Week Low | $15.01 | $5.51 |
| 52 Week High | $27.76 | $14.38 |
| Indicator | CAAP | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 86.54 |
| Support Level | $25.16 | $14.30 |
| Resistance Level | $27.31 | $14.38 |
| Average True Range (ATR) | 0.78 | 0.05 |
| MACD | -0.20 | -0.15 |
| Stochastic Oscillator | 36.15 | 68.69 |
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.